Drug Trial Radar · NCT06202079
A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Jan 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
179
Actual
Start
Aug 11, 2023
Primary completion
Jul 13, 2024
Study completion Aug 8, 2024
Sponsor
- Lead sponsor
- Gan and Lee Pharmaceuticals, USAIndustry
- Sponsor type
- Industry
- First posted
- Jan 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares the efficacy, safety, and tolerability of once-weekly GZR4 Injection versus once-daily insulin degludec in patients with type 2 diabetes mellitus in inadquete control on oral antidiabetic drug (OAD) therapy or OAD Therapy in combination with basal insulin.
Conditions
- Diabetes Mellitus, Type 2
Interventions
GZR4 InjectionDrug
GZR4 injection s.c., once-weekly, treat-to-target dose
Insulin DegludecDrug
Insulin Degludec s.c., once-daily, treat-to-target dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: From baseline (week 0) to week 16
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Study Site 02
Beijing, China
Study Site 05
Beijing, China
Study Site 01
Tianjin, China
Study Site 07
Wuhan, Hubei, China
Study Site 06
Changzhou, Jiangsu, China
Study Site 08
Jinan, Shandong, China
Study Site 04
Zibo, Shandong, China
Study Site 03
Xi’an, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.